Federal Circuit Affirms in Edwards Lifesciences v. Meril: TAVR Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Edwards Lifesciences Co. v. Meril Life Sciences Pvt. Ltd. |
| Case Number | 22-1877 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from D. Del. |
| Duration | June 7, 2022 – March 25, 2024 657 Days / 22 Months |
| Outcome | Plaintiff Win – Affirmed |
| Patents at Issue | |
| Accused Products | Meril’s Myval aortic valve repair devices and associated Myval delivery systems and components |
Case Overview
The Parties
⚖️ Plaintiff
Global leader in structural heart disease therapies, headquartered in Irvine, California. Pioneers in transcatheter heart valve technology with an extensive IP portfolio.
🛡️ Defendant
India-based medical device manufacturers of the Myval transcatheter heart valve system, competing in the TAVR market.
Patents at Issue
This landmark case involved five foundational U.S. patents covering heart valve technology and delivery systems — a domain where Edwards Lifesciences has long held dominant IP positions.
- • US6878168B2 — Covers transcatheter heart valve structures
- • US10292817B2 — Covers aspects of TAVR implantation methods
- • US9393110B2 — Details catheter-based delivery system components
- • US9119716B2 — Further covers heart valve technology
- • US10053256B2 — Additional claims on TAVR delivery system components
Developing a TAVR device?
Check if your medical device design might infringe these or related patents before clinical trials or market entry.
The Verdict & Legal Analysis
Outcome
The Federal Circuit affirmed the prior ruling, and the appeal was dismissed — effectively upholding Edwards Lifesciences’ position in this infringement action. No specific damages amount was publicly disclosed in the case record provided. Injunctive relief details were not specified in the available case data.
Key Legal Issues
The Federal Circuit’s affirmance signals that Meril’s appellate arguments — whether challenging claim construction, non-infringement findings, or patent validity — did not persuade the court to disturb the lower court’s conclusions. This procedurally meaningful outcome strengthens the enforceability of Edwards’ five asserted patents.
An affirmed infringement ruling across a five-patent portfolio in the TAVR space reinforces that broad foundational patents in pioneered medical device categories can withstand appellate scrutiny when properly prosecuted and asserted. It also highlights that multi-patent assertion strategies — covering both device structures and delivery systems — create layered infringement exposure that is difficult to design around comprehensively.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in TAVR device design. Choose your next step:
📋 Understand TAVR Patent Landscape
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in TAVR IP
- Understand claim construction patterns for medtech
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own TAVR device or technology.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
TAVR Device Structures & Delivery
5 Patents at Issue
Covering core TAVR technology
Rigorous FTO Critical
Before market entry & regulatory submission
✅ Key Takeaways
Affirmed multi-patent infringement actions at the Federal Circuit strengthen portfolio enforceability and deter future challenges.
Search related case law →Appeal dismissal — rather than full merits review — reflects the difficulty of overcoming well-developed lower court records.
Explore precedents →TAVR patent litigation precedents are accumulating rapidly; monitor related Edwards Federal Circuit docket activity.
Track MedTech cases →Frequently Asked Questions
Five U.S. patents: US6878168B2, US10292817B2, US9393110B2, US9119716B2, and US10053256B2, covering transcatheter aortic valve structures and delivery systems.
The Court of Appeals for the Federal Circuit affirmed the lower court ruling and dismissed Meril’s appeal on March 25, 2024.
It reinforces multi-patent portfolio enforcement as an effective deterrent and raises the strategic importance of pre-market FTO clearance for all TAVR competitors.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case No. 22-1877
- USPTO Patent Search
- U.S. Patent and Trademark Office — Patent Resources
- PatSnap — IP Intelligence Solutions for Medical Devices
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.